MGNX

Flotetuzumab

Acute myeloid leukemia

Phase 2

Exp Date

Q4 2020

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Flotetuzumab in Acute myeloid leukemia - Phase 2 Data

  • ClinicalTrial.gov (NCT03739606): Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer


WHAT IS THE CATALYST EVENT?

  • Phase 2 Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA/EVENTS

PRESS RELEASE

POSTERS


PUBLICATIONS



MECHANISM OF ACTION / RATIONALE

  • Flotetuzumab is a humanized DART® molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, has been reported to be over-expressed on cancer cells in a wide range of hematological malignancies including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). AML and MDS are thought to arise in and be perpetuated by a small population of leukemic stem cells (LSCs) that generally resist conventional chemotherapeutic agents. LSCs are characterized by high levels of CD123 expression that is low or absent in the corresponding hematopoietic progenitors and stem cell populations in normal human bone marrow.

Updated by HC

#MGNX

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon